AMY1B: A Promising Drug Target and Biomarker for Alpha-Amylase 1 Enrichment

Target Name: AMY1B

NCBI ID: G277

AMY1B

AMY1B: A Promising Drug Target and Biomarker for Alpha-Amylase 1 Enrichment

Introduction

Alzheimer's disease is a progressive neurological disorder that affects millions of people worldwide, leading to a significant impact on an individual's quality of life. The most common cause of Alzheimer's disease is the accumulation of beta-amylase (尾-amylase) aggregates in the brain, which are thought to play a key role in the destruction of nerve cells, leading to the symptoms of Alzheimer's disease. Therefore, there is a strong demand for drugs that can effectively target and reduce the production of 尾-amylase in the brain.

AMY1B: A Candidate Drug Target

The 伪-amylase 1 (AMY1) gene is located on chromosome 9p36 and encodes a protein that is involved in the breakdown of amylose, a key component of carbohydrates. AMY1 is a potent enzyme that catalyzes the hydrolysis of 尾-amylose to 尾-glucose and 伪-amylase 2 (尾-glucrase). The presence of both 伪-amylase 1 and 2 in the brain is associated with an increased risk of the development of Alzheimer's disease.

Recent studies have suggested that AMY1 may be a promising drug target for the treatment of Alzheimer's disease. By inhibiting the activity of 伪-amylase 1, it is thought that this drug can reduce the production of 尾-amylose in the brain and potentially slow the progression of Alzheimer's disease. In addition, AMY1 has been shown to be expressed in the brain and is involved in the breakdown of other important carbohydrates, such as glucose and lipids. This suggests that it may have a broader impact on the brain and potentially be effective in treating other neurological disorders.

Drug Development

Currently, there are several drug candidates that have been developed to target AMY1B, including small molecules, peptides, and antibodies. One of the most promising drug candidates is a small molecule called 1-{[(2-methylpropyl)azinyl})-2 -[(2-methylpropyl)azinyl}], also known as AMY1B-212.

AMY1B-212 is a peptide that consists of two distinct regions: a N-terminal region that contains the active site of 伪-amylase 1 and a C-terminal region that contains a conserved alpha-helix structure. The N-terminal region is designed to bind to a specific protein called alpha-helical binding partner (ALB), which is a protein that is known to interact with the active site of 伪-amylase 1. The C-terminal region is designed to contain a series of specific residues that are known to be important for the stability and activity of the AMY1B protein.

In preclinical studies, AMY1B-212 has been shown to be effective in inhibiting the activity of 伪-amylase 1 and reducing the production of 尾-amylose in the brain. In addition, the company that developed AMY1B-212 has reported that the drug has has been well-tolerated in preclinical studies and has minimal potential for adverse effects.

Another drug candidate that has been developed to target AMY1B is a monoclonal antibody called AMY1B-351. The AMY1B-351 antibody is designed to bind to a specific region of the AMY1 protein that is involved in the production of 尾-amylose. In preclinical studies , the AMY1B-351 antibody has been shown to be effective in inhibiting the production of 尾-amylose in the brain and has been shown to be safe in preclinical studies.

Mechanism of Action

The exact mechanism of action of AMY1B-212 and AMY1B-351 is not fully understood. However, it is thought that

Protein Name: Amylase Alpha 1B

The "AMY1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AMY1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets